Skip to main content

Table 1 Patient background characteristics (n = 53)

From: Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations

Variable Rebiopsy
(+) (−)
T790M mutation
Positive
(n = 29)
Negative
(n = 17)
Unknown
(n = 7)
Sex
 Male 11 3 3
 Female 18 14 4
 Age (years) median (range) 74 (42 - 86) 72 (38 - 89) 70 (59 - 82)
Histology
 Adenocarcinoma 27 17 7
 others 2 0 0
EGFR mutation at initial diagnosis
 Exon 19 deletion 21 6 1
 L858R 8 9 5
 L861Q 0 1 0
 Exon 20 insertion 0 1 0
 Compound mutation 0 0 1
Smoking status
 Never 18 13 3
 Past 8 1 2
 Current 3 3 2
ECOG performance status
 0 20 12 3
 1 8 5 2
 2 1 0 1
 3 0 0 1
Stage at initial diagnosis
 IA - IIIC 10 3 3
 IVA - IVB 19 14 4
Surgical treatment
 No 13 6 3
 Yes 16 11 4
Radical Radiotherapy
 No 27 16 6
 Yes 2 1 1
Chemotherapy during treatment
 No 8 6 6
 Yes 21 11 1
Reason for termination of TKIs
 Ongoing 1 5 3
 Adverse events 0 1 3
 Tumor growth 14 3 0
 New lesions 14 8 1
“CEA at progression” / “nadir CEA”; median (range) 3.1 (1.1–170) 2.5 (1.3–7.88) 2.0 (0.5–3.57)
nadir CEA (ng/mL); median (range) 3.0 (0.8–36.9) 2.2 (1.0–78.9) 45.6 (1.4–198)
Medical Drugs at TKI naïve line
 Gefitinib 11 2 0
 Erlotinib 16 10 6
 Afatinib 2 5 1
  1. Abbreviations: ECOG Eastern Cooperative Oncology Group; TKI tyrosine kinase inhibitor; CEA carcinoembryonic antigen; “CEA at progression” / “nadir CEA” “Serum level of CEA at progression” divided by “Serum nadir level of CEA”; nadir CEA Serum nadir level of CEA